tulobuterol
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
2
Earliest trial started Sep 1, 2003 (NCT00950794)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Beta-2 adrenergic receptorAGONIST
Beta-2 adrenergic receptor agonist
- Beta-2 adrenergic receptorANTAGONIST
ADRB2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)NCC(O)c1ccccc1Cl- Mol. weight
- 227.74 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1159717 ↗
- ChEMBLCHEMBL1256478 ↗
Also known as
- 1-(o-chlorophenyl)-2-tert-butylaminoethanol
- 2-chloro-alpha-(((1,1-dimethylethyl)amino)methyl)benzenemethanol
- alpha-((tert-butylamino)methyl)-o-chlorobenzyl alcohol
- atenos
- brelomax
- brelomax
- brelomax
- c-78
- hn-078
- hokunalin
- hokunalin
- hokunalin
- hokunalin
- respacal
- respacal
- tulobuterol
- tulobuterol
- tulobuterol
- tulobuterol
- tulobuterol
- tulobuterol
- tulobuterol
- (+/-)-tulobuterol
- tulobuterol hcl
- tulobuterol hcl
- tulobuterol hcl
- tulobuterol hydrochloride
- tulobuterol hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04057469 | N/A | Aug 20, 2019 | Seoul National University |
| NCT01465906 | Phase 4 | Nov 1, 2010 | Fudan University |
| NCT00950794 | Phase 4 | Sep 1, 2003 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2003 |
| Seoul National University | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1